Protalix BioTherapeutics to Present at the 3rd Annual H.C. Wainwright BioConnect Investor Conference at Nasdaq NYC

CARMIEL, Israel, May 14, 2025 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell–based protein expression system, today announced that it will participate in the 3rd Annual H.C. Wainwright BioConnect Investor Conference, taking place on Tuesday, May 20, 2025 at the Nasdaq headquarters in New York City, New York.
Eyal Rubin, the Company's Sr. Vice President and Chief Financial Officer, will deliver a company presentation and be available for one-on-one investor meetings throughout the event.
Investors interested in scheduling a meeting with the Company's management team should contact their H.C. Wainwright representative or email meetings@hcwco.com.
Event Details
Conference: 3rd Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 20, 2025
Location: Nasdaq World Headquarters in New York City (151 W. 43rd Street)
Webcast Details
A webcast of the live presentation will be available at 4:30 pm, Eastern Daylight Time (EDT), via the following links:
Company Link: https://ir.protalix.com/news-events/events
Webcast Link: https://journey.ct.events/view/c15f7813-e688-4a3e-911e-358a9c0562b8
About Protalix BioTherapeutics, Inc.
Protalix is a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx. It is the first company to gain U.S. Food and Drug Administration (FDA) approval of a protein produced through plant cell-based in suspension expression system. This unique expression system represents a new method for developing recombinant proteins in an industrial-scale manner. Protalix has licensed to Pfizer Inc. the worldwide development and commercialization rights to taliglucerase alfa for the treatment of Gaucher disease, Protalix's first product manufactured through ProCellEx, excluding in Brazil, where Protalix retains full rights. Protalix's second product, Elfabrio®, was approved by both the FDA and the European Medicines Agency in May 2023.
Protalix has partnered with Chiesi Farmaceutici S.p.A. for the global development and commercialization of Elfabrio. Protalix's development pipeline consists of proprietary versions of recombinant therapeutic proteins that target established pharmaceutical markets, including the following product candidates: PRX–115, a plant cell-expressed recombinant PEGylated uricase for the treatment of uncontrolled gout; PRX–119, a plant cell-expressed long acting DNase I for the treatment of NETs-related diseases; and others.
Investor Contact: Mike Moyer, Managing DirectorLifeSci Advisors+1-617-308-4306 mmoyer@lifesciadvisors.com
Logo: https://mma.prnewswire.com/media/999479/Protalix_Biotherapeutics_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/protalix-biotherapeutics-to-present-at-the-3rd-annual-hc-wainwright-bioconnect-investor-conference-at-nasdaq-nyc-302455102.html
SOURCE Protalix BioTherapeutics, Inc.

Try Our AI Features

Explore what Daily8 AI can do for you:

Learn with AIFact CheckingText to SpeechAI Summary

Related Articles

USA Today

20 minutes ago

• USA Today

Novo Nordisk halts Wegovy deal with Hims & Hers, triggering 31% stock drop

Drugmaker Novo Nordisk said on Monday it would halt its Wegovy weight-loss drug agreement with U.S. telehealth company Hims & Hers Health HIMS.N, pushing Hims shares down 31% in morning trading. The two companies had announced a collaboration in April for Hims & Hers to sell Novo's Wegovy through a bundled offering on the telehealth company's platform. The end of the collaboration means Hims will no longer be able to sell branded Wegovy drugs. Novo said that Hims & Hers' decision to continue supplying doses of compounded semaglutide - the active ingredient in Wegovy - was not in accordance with the law because the drug was no longer in shortage. The U.S. Food and Drug Administration had allowed compounded versions made by pharmacies during the drug's shortage. In case you missed it: Wegovy weight-loss drug discounted to $199 until July, but there's a catch Earlier this month, Hims said that it would continue selling "personalized" doses of semaglutide, starting at around $165 a month. Hims has said personalized doses are allowed for patients who need different doses for clinical reasons such as limiting side effects. Hims & Hers shares were trading at $44.55 on Monday. Hims also sells liraglutide, a generic version of another older Novo diabetes drug that causes weight loss, as well as Eli Lilly's LLY.N rival Zepbound. Wall Street analysts have questioned whether Hims' offerings actually qualify as "personalized" and say it is unclear if Novo, which has said mass production of copies is breaking the law, will allow it. Hims & Hers was not immediately available for a comment. A U.S. federal judge on Friday rejected a bid by compounding pharmacies to allow them to continue making copies of Novo Nordisk's weight-loss drugs Ozempic and Wegovy, upholding the U.S. Food and Drug Administration's decision to remove the drugs' active ingredient, semaglutide, from the shortage list. "Efforts will continue to make authentic, FDA-approved Wegovy directly available through NovoCare Pharmacy to select telehealth organizations that share our commitment to safe and effective medical treatment for patients," Novo said. Novo's share price fell following the announcement, extending an earlier decline to trade down 6.5% by 1315 GMT. Shares of Hims & Hers fell 22% to $50.02 in U.S. premarket hours. Reporting by Louise Breusch Rasmussen, Bhanvi Satija and Amina Niasse; Editing by Terje Solsvik, Catherine Evans and Aidan Lewis

Yahoo

24 minutes ago

• Yahoo

WorkWave Opens Registration and Announces Keynote Speaker for its Annual Beyond Service Customer Conference

The 2026 Beyond Service Customer Conference will ignite innovation and drive transformation, uniting customers as they collaborate, share real-world insights, and explore innovative trends and strategies in field service. HOLMDEL, N.J., June 23, 2025 /PRNewswire/ -- WorkWave®, a leading provider of software and solutions that help mobile service companies thrive, has opened registration for its 2026 Beyond Service Customer Conference, inviting its customers to attend the three-day event filled with learning, networking and collaboration. The conference will be held February 1-4, 2026, at the Hilton Anatole in Dallas, TX. WorkWave leadership, experts and customers from its family of brands, including PestPac, RealGreen and TEAM Software, will all be in attendance. "At WorkWave, we know that the work our customers perform every day is essential in keeping the world safe, clean and beautiful," says CEO Kevin Kemmerer. "Our mission is to support and provide value to our customers by not only delivering innovative software and fintech solutions, but also creating an event experience where they can learn, grow and be inspired. As the field service industry continues to face new challenges, technologies and economic factors, it is pivotal we help enable our customers to tap into their innovative spirit that will take our industries to new levels of growth, efficiency and success." Kemmerer, joined by WorkWave executives Robbie Hobbs (CPO), John Phelan (CTO) and others, will headline the Beyond Service stage. They will deliver invaluable insights into our software, outlining the future of WorkWave and presenting on the pivotal roles of data and AI in our products, the importance of fintech in field service, and overarching industry trends relevant to all WorkWave customers. WorkWave is dedicated to its customer-first mentality, with a focus on customer-led sessions and strategic, actionable insights. Sessions will include tracks for executive-level attendees seeking big-picture strategy and fresh, new ideas; front- and back-office users across all specialties to help maximize the day-to-day impact of our software solutions; customers interested in M&A-based growth or PE-backed opportunities; and more. WorkWave has also announced Shawn Kanungo as this year's keynote speaker. Kanungo is a widely recognized innovation strategist and bestselling author, and has emerged as one of the world's most sought-after voices on innovation and generative AI. With WorkWave's newest offering, Wavelytics, providing unmatched data and AI capabilities to its customers, it's critical for customers to understand the depth of AI and data and how it will bring value to their businesses. "AI is going to transform jobs across all industries, including those in field service, and it is absolutely crucial that these industries realize the full potential and benefits of this technology if they want to grow and outperform their competitors," says Kanungo. "I'm thrilled to be speaking at the Beyond Service Customer Conference and cannot wait for the opportunity to share my knowledge with WorkWave customers and help them bring the best in technology to their business." Other highlights for the 2026 conference include: Tailored and immersive product bootcamps for every skill level Thought leadership sessions that address key industry challenges and provide actionable insight Product-specific sessions to empower customers with the knowledge to master their software Opportunities for 1:1 meetings with product experts Networking events with industry peers and nightly entertainment Early bird pricing for the 2026 Beyond Service Customer Conference starts June 23, 2025, and ends August 31, 2025. Please visit our website to learn more, and click here to register for the event. Our website will continue to be updated with this year's agenda, session information and other details. About WorkWave WorkWave delivers innovative software and fintech solutions to the millions of hardworking service professionals that keep the world safe, clean and beautiful. Partnering with thousands of customers worldwide, the leading lawn care, pest control, commercial cleaning and security guarding companies rely on its end-to-end SaaS solutions to run and grow their businesses – everything from customer acquisition to mobile communications to billing and invoicing, and beyond. Backed by decades of experience, passionate teams, and strong commitment to its customers, WorkWave's vision is to empower the world's mobile service workers to build a brighter future. For more information, visit Media Contact press@ View original content to download multimedia: SOURCE WorkWave Sign in to access your portfolio

Business Wire

44 minutes ago

• Business Wire

NYSE: HIMS Investigation Alert: Kessler Topaz Meltzer & Check, LLP Encourages Hims & Hers Health, Inc. (NYSE: HIMS) Investors with Significant Losses to Contact the Firm

RADNOR, Pa.--(BUSINESS WIRE)--The law firm of Kessler Topaz Meltzer & Check, LLP ( is currently investigating potential violations of the federal securities laws on behalf of investors of Hims & Hers Health, Inc. (NYSE: HIMS) ('Hims & Hers'). On June 23, 2025, during pre-market hours, the pharmaceutical company Novo Nordisk announced it would no longer provide Hims & Hers with direct access to its FDA-approved weight loss drug Wegovy through NovoCare Pharmacy due to concerns about illegal mass compounding and deceptive marketing by Hims & Hers. Specifically, Novo Nordisk explained that Hims & Hers allegedly failed to comply with laws prohibiting mass sales of compounded drugs and disseminated 'deceptive marketing that put patient safety at risk." On this news, Hims and Hers stock price fell over 20% during intraday trading on June 23, 2025. If you are a Hims & Hers investor and would like to learn more about our investigation, please CLICK HERE to fill out our online form or contact Kessler Topaz Meltzer & Check, LLP: Jonathan Naji, Esq. (484) 270-1453 or E-mail at info@ You can also click on the following link or paste it in your browser: Kessler Topaz Meltzer & Check, LLP prosecutes class actions in state and federal courts throughout the country involving securities fraud, breaches of fiduciary duties and other violations of state and federal law. Kessler Topaz Meltzer & Check, LLP is a driving force behind corporate governance reform, and has recovered billions of dollars on behalf of institutional and individual investors from the United States and around the world. The firm represents investors, consumers and whistleblowers (private citizens who report fraudulent practices against the government and share in the recovery of government dollars). For more information about Kessler Topaz Meltzer & Check, LLP, please visit May be considered attorney advertising in certain jurisdictions. Past results do not guarantee future outcomes.